{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-24-025262","form_type":"8-K","ticker":"ABBV","cik":"0001551152","company_name":"AbbVie Inc.","filed_at":"2024-02-20T23:59:59+00:00","discovered_at":"2026-05-14T18:03:24.574425+00:00","generated_at":"2026-06-05T23:03:38.231620+00:00","sec_items":["5.02","7.01","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"AbbVie names Robert Michael as CEO effective July 1; Gonzalez to executive chairman","bullets":["Robert A. Michael, current president & COO, will become CEO on July 1, 2024.","Richard A. Gonzalez retires as CEO after 11 years, becomes executive chairman.","Michael appointed to board as Class II director, effective July 1, 2024.","Gonzalez to remain as executive chairman; board conducted thorough succession process.","Michael played key role in Allergan, ImmunoGen, and pending Cerevel acquisitions."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-24-025262","json":"https://secwatch.observer/filing/0001104659-24-025262.json","markdown":"https://secwatch.observer/filing/0001104659-24-025262.md","text":"https://secwatch.observer/filing/0001104659-24-025262.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1551152/000110465924025262/0001104659-24-025262-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1551152/000110465924025262/tm246649d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-05T23:03:38.231620+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"9b42f83e27","claim":"Robert A. Michael was appointed as Director at AbbVie Inc..","evidence_excerpt":"The Board also appointed Mr. Michael as a member of the Board of Directors as a Class II director, effective July 1, 2024.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1551152/000110465924025262/0001104659-24-025262-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"a1c951cc62","claim":"Richard A. Gonzalez changed role as Executive Chairman at AbbVie Inc..","evidence_excerpt":"Mr. Gonzalez, who has served as CEO since the company’s formation in 2013, will retire from the role of CEO and become Executive Chairman of the Board of Directors, effective July 1, 2024.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1551152/000110465924025262/0001104659-24-025262-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"become"},{"label":"Role","value":"Executive Chairman"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}